A New Era of Biopharma Production with AI
The launch of our third Digital Accelerator, dedicated to the digital transformation of our global Manufacturing & Supply (M&S) network, marks a pivotal step in Sanofi’s journey to become the first biopharma company powered by AI at scale.
How Sanofi is Scaling AI to Transform Medicine Development and Delivery
Our bold ambition is clear: accelerate the path from scientific discovery to patient delivery by embedding Artificial Intelligence into every facet of pharmaceutical production — reducing time-to-market, increasing efficiency, and bringing life-saving treatments to patients faster.
Through our growing network of Digital Accelerators, Sanofi is driving a dual transformation: making medicines faster and more efficiently for people across the globe, while embedding a digital-first mindset throughout the company to harness the full potential of tomorrow’s scientific and technological breakthroughs.
Accelerating Innovation to Bring Life-Saving Therapies Closer
In the fast-changing world of biopharma, patients can’t wait. Speed and precision are more than competitive advantages — they’re imperatives. That’s why we are transforming our industrial network, using digital tools to meet the urgent needs of patients and healthcare systems worldwide.
This new Accelerator is a major strategic lever for integrating digital agility into every link of our manufacturing value chain. It enables us to bring our innovations to patients faster, with more agile, robust, and predictive production.
Brendan O’Callaghan
Executive Vice President, Manufacturing and Supply
Smarter, Faster, Scalable: AI in Action
We’re applying AI across the entire development lifecycle — from early research to commercial manufacturing — to shorten the time it takes to bring new medicines to market by up to one year. We’re aiming to triple the number of new medicines we launch, proof of our unwavering commitment to innovation.
At our newest Digital M&S Accelerator in Lyon (France), a cross-functional team of experts in data science, software engineering, and user experience working in a startup like environment is deploying Digital twins for virtual production simulations, AI + Internet of Things (IoT) for real-time monitoring and predictive decision-making and scalable platforms to enhance global supply chain resilience.
Proven Impact: From Personalized Medicine to AI-Enhanced R&D
Since 2022, our patient-centric accelerator has deepened our understanding of patient and healthcare provider needs, helping drive treatment adoption.
Our second accelerator, launched in early 2024 and focused on R&D has already identified seven new therapeutic targets. Our Patient Digital Twin technology has also improved predictive accuracy, paving the way for more personalized medicine.
This new accelerator fully embodies our 'AI-first' strategy, which aims to make artificial intelligence a structuring driver of our transformation. By anchoring AI at the heart of our operations, we are reinventing our processes, accelerating decision-making, and creating conditions for faster innovation for patients.
Emmanuel Frenehard
Executive Vice President, Chief Digital Officer
Building the Future: Scaling AI for Next-Gen Healthcare Innovation
Our AI-driven transformation is just beginning. As we scale these technologies globally, we invite partners, innovators, and healthcare professionals to join us on this journey. Together, we can shape the future of medicine — where AI accelerates discovery, improves care, and ultimately delivers better outcomes for patients everywhere.